Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Xu, L ^a   Feng, J M ^a   Li, J X ^a   Zhu, J M ^a   Song, S S ^a   Tong, L J ^a   Chen, Y ^a   Yang, X Y ^a   Shen, Y Y ^a   Lian, F L ^a   Li, Y P ^a   Lin, D H ^a   Ding, J ^a   Miao, Z H ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AKT; ERK; Multidrug resistance; p38; Stat3; Tanshinone 1

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATASE; PROTEIN KINASE B; SELUMETINIB; STAT3 PROTEIN; TANSHINONE I; VERAPAMIL; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DITERPENES, ABIETANE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICE; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84889578982     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.443     Document Type: Article

References (59)

1. Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat 2012; 15: 98-105
2. Brozik A, Hegedus C, Erdei Z, Hegedus T, Ozvegy-Laczka C, Szakacs G, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: Substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011; 7: 623-642
3. Gillet JP, Gottesman MM. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Drug Resist Updat 2012; 15: 2-4
4. Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE. Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist Updat 2012; 15: 50-61
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58
6. Miao ZH, Tang T, Zhang YX, Zhang JS, Ding J. Cytotoxicity apoptosis induction and downregulation of MDR-1 expression by the anti-Topoisomerase II agent, salvicine, in multidrug-resistant tumor cells. Int J Cancer 2003; 106: 108-115
7. Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003; 63: 4527-4532
8. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin down-regulates the multidrugresistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 2008; 259: 111-118
9. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, et al. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: A novel function-converter model. J Mol Med (Berl) 2012; 90: 971-981
10. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105
11. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904-910
12. Levy DE, Darnell JE. STATs: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662
13. Yue P, Turkson J. Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs 2009; 18: 45-56
14. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009; 50: 1861-1870
15. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010; 102: 1592-1599
16. Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012; 30: 916-926
17. Jiang Y, Miao ZH, Xu L, Yu B, Gong JX, Tong LJ, et al. Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J Biol Chem 2011; 286: 26461-26469
18. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discov 2012; 2: 694-705
19. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10: 127-140
20. Lu Y, Zhou J, Xu C, Lin H, Xiao J, Wang Z, et al. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 2008; 21: 305-314
21. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488
22. Dong Y, Morris-Natschke SL, Lee KH. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep 2011; 28: 529-542
23. Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007; 27: 133-148
24. Wu LC, Lin X, Sun H. Tanshinone IIA protects rabbits against LPS-induced disseminated intravascular coagulation (DIC). Acta Pharmacol Sin 2012; 33: 1254-1259
25. Lee WY, Zhou X, Or PM, Kwan YW, Yeung JH. Tanshinone I increases CYP1A2 protein expression and enzyme activity in primary rat hepatocytes. Phytomedicine 2012; 19: 169-176
26. Nizamutdinova IT, Lee GW, Son KH, Jeon SJ, Kang SS, Kim YS, et al. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptornegative (MDA-MB-231) breast cancer cells. Int J Oncol 2008; 33: 485-491
27. Nizamutdinova IT, Lee GW, Lee JS, Cho MK, Son KH, Jeon SJ, et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 2008; 29: 1885-1892
28. Li Y, Gong Y, Li L, Abdolmaleky HM, Zhou Jr. Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog 2012; 52: 535-543
29. Lee CY, Sher HF, Chen HW, Liu CC, Chen CH, Lin CS, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 2008; 7: 3527-3538
30. Hegewisch-Becker S, Hanania EG, Fu S, Korbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: Use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 1995; 90: 876-883
31. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234
32. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236
33. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Cancer Res 2011; 17: 483-493
34. Zhang X, Xiao W, Wang L, Tian Z, Zhang J. Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via downregulating P-gp. PLoS One 2011; 6: E20965
35. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kalai T, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011; 12: 837-845
36. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 2010; 16: 5189-5199
37. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326
38. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res 2006; 66: 4826-4834
39. Bhattacharjee A, Xu B, Frank DA, Feldman GM, Cathcart MK. Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with protein kinase C delta and tyrosine-phosphorylated Stat3. J Immunol 2006; 177: 3771-3781
40. Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z, et al. A peroxisome proliferatoractivated receptor-gamma agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-Tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006; 281: 6165-6174.
41. Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol 2012; 227: 2184-2195
42. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429: 403-417
43. Chen J. Multiple signal pathways in obesity-Associated cancer. Obes Rev 2011; 12: 1063-1070
44. Kristensen DM, Kalisz M, Nielsen JH. Cytokine signalling in embryonic stem cells. APMIS 2005; 113: 756-772
45. Dhingra S, Bagchi AK, Ludke AL, Sharma AK, Singal PK. Akt regulates IL-10 mediated suppression of TNFalpha-induced cardiomyocyte apoptosis by upregulating Stat3 phosphorylation. PLoS One 2011; 6: E25009
46. Sun HZ, Xu L, Zhou B, Zang WJ, Wu SF. Depletion of insulin receptor substrate 2 reverses oncogenic transformation induced by v-src. Acta Pharmacol Sin 2011; 32: 611-618
47. Wu CP, Hsieh CH, Wu YS. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm 2011; 8: 1996-2011
48. Beumer JH, Franke NE, Tolboom R, Buckle T, Rosing H, Lopez-Lazaro L, et al. Disposition and toxicity of trabectedin (ET-743) in wild-Type and mdr1 gene (P-gp) knock-out mice. Invest New Drugs 2010; 28: 145-155
49. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008; 4: 682-690
50. Wang Z, Liu J, Yu Y, Chen Y, Wang Y. Modular pharmacology: The next paradigm in drug discovery. Expert Opin Drug Discov 2012; 7: 667-677
51. Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, et al. BB, a new EGFR inhibitor, exhibits prominent anti-Angiogenesis and antitumor activities. Cancer Biol Ther 2009; 8: 1640-1647
52. Manzo SG, Zhou ZL, Wang YQ, Marinello J, He JX, Li YC, et al. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res 2012; 72: 5363-5373
53. Smit LA, Bende RJ, Aten J, Guikema JE, Aarts WM, van Noesel CJ. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. Cancer Res 2003; 63: 3894-3898
54. Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ, Qu CK. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 2007; 109: 778-785
55. Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA, et al. Dynamin 2 mediates PDGFRalpha-SHP-2-promoted glioblastoma growth and invasion. Oncogene 2012; 31: 2691-2702
56. Eden ER, White IJ, Tsapara A, Futter CE. Membrane contacts between endosomes and ER provide sites for PTP1B-epidermal growth factor receptor interaction. Nat Cell Biol 2010; 12: 267-272
57. Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, et al. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Clin Cancer Res 2007; 13: 10
58. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98: 295-303
59. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009; 15: 283-293